Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Timber Pharmaceuticals Inc (TMBR)
Timber Pharmaceuticals Inc (TMBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,176
  • Shares Outstanding, K 3,433
  • Annual Sales, $ 80 K
  • Annual Income, $ -19,380 K
  • 60-Month Beta 0.03
  • Price/Sales 14.07
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade TMBR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.11
  • Most Recent Earnings $-1.27 on 08/21/23
  • Latest Earnings Date 12/04/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3202 +10.31%
on 11/28/23
2.8737 -87.71%
on 10/30/23
-2.3518 (-86.94%)
since 10/27/23
3-Month
0.3202 +10.31%
on 11/28/23
3.2500 -89.13%
on 08/30/23
-2.8868 (-89.10%)
since 08/29/23
52-Week
0.3202 +10.31%
on 11/28/23
3.3900 -89.58%
on 02/28/23
-1.0068 (-74.03%)
since 11/28/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CTG : 10.50 (+0.10%)
ESTE : 21.17 (+0.47%)
PR : 15.05 (+0.20%)
TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals’ (NYSE American: TMBR) Phase 3 ASCEND Study for TMB-001: A Leap Forward in Congenital Ichthyosis Treatment

Significant Progress in Timber Pharmaceuticals' Phase 3 ASCEND Study Timber Pharmaceuticals (NYSE American: TMBR), a clinical-stage biopharmaceutical company specializing in

TMBR : 0.3426 (+0.74%)
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 1.33% and 8.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RVNC : 5.49 (+3.39%)
TMBR : 0.3426 (+0.74%)
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of -9.09% and 7.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 9.51 (-3.26%)
TMBR : 0.3426 (+0.74%)
Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now

Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals (NYSE American: TMBR) Granted Orphan Drug Designation in Europe for TMB-001

Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is engaged as a clinical-stage biopharmaceutical company, which is focused on the development and

TMBR : 0.3426 (+0.74%)
The Worst Biotech Stocks Investors Could Buy This Fall

Timber Pharmaceuticals (TMBR) recently received an NYSE warning for not meeting the minimum trading price requirement for quite some time. The stock has lost 84% year-to-date. Given the company’s weak...

BIIB : 223.32 (+0.38%)
GILD : 73.55 (+1.06%)
TMBR : 0.3426 (+0.74%)
VRTX : 430.11 (+0.78%)
4 Stocks That Have Taken a Turn for the Worse in 2022

The Fed’s hawkish stance on inflation has raised the likelihood of a recession in the near term. Fundamentally weak stocks Marvell Technology (MRVL), Plug Power (PLUG), Riot Blockchain (RIOT), and Timber...

MRVL : 67.58 (-3.28%)
PLUG : 3.01 (-3.83%)
RIOT : 14.85 (-5.59%)
TMBR : 0.3426 (+0.74%)
2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech...

BIIB : 223.32 (+0.38%)
TMBR : 0.3426 (+0.74%)
VRTX : 430.11 (+0.78%)
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 11.11% and 2.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO : 15.00 (unch)
TMBR : 0.3426 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Timber Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company is initially engaged on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, tuberous...

See More

Key Turning Points

3rd Resistance Point 0.3848
2nd Resistance Point 0.3674
1st Resistance Point 0.3550
Last Price 0.3426
1st Support Level 0.3252
2nd Support Level 0.3078
3rd Support Level 0.2954

See More

52-Week High 3.3900
Fibonacci 61.8% 2.2173
Fibonacci 50% 1.8551
Fibonacci 38.2% 1.4929
Last Price 0.3426
52-Week Low 0.3202

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar